KR100460583B1 - 간세포 암의 예방 및 치료 방법 - Google Patents
간세포 암의 예방 및 치료 방법 Download PDFInfo
- Publication number
- KR100460583B1 KR100460583B1 KR10-1999-7008375A KR19997008375A KR100460583B1 KR 100460583 B1 KR100460583 B1 KR 100460583B1 KR 19997008375 A KR19997008375 A KR 19997008375A KR 100460583 B1 KR100460583 B1 KR 100460583B1
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- residues
- cells
- peptide
- alphafetoprotein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (16)
- 암세포에 대해 알파페토프로테인 펩티드 특이적 T 림프구를 활성화시키는 것을 포함하는 면역 반응을 생성시키기에 충분한 알파페토프로테인 분자의 아미노산 서열의 일부 또는 이의 변형체를 포함하며, 알파페토프로테인 분자의 아미노산 서열의 일부가 SEQ ID NO:2의 잔기 1-9, SEQ ID NO:2의 잔기 12-20, SEQ ID NO:2의 잔기 158-166, SEQ ID NO:2의 잔기 178-186, SEQ ID NO:2의 잔기 235-243, SEQ ID NO:2의 잔기 287-295, SEQ ID NO:2의 잔기 404-412, SEQ ID NO:2의 잔기 441-450, SEQ ID NO:2의 잔기 492-500, SEQ ID NO:2의 잔기 542-550, SEQ ID NO:2의 잔기 547-556 및 SEQ ID NO:2의 잔기 555-563으로 구성된 군으로부터 선택되고, 변형체가 SEQ ID NO:3 또는 SEQ ID NO:4인, 포유동물의 암을 예방하거나 치료하기 위한 약제 조성물.
- 제 1항에 있어서, 알파페토프로테인 펩티드 특이적 T 림프구가 세포독성 T 림프구임을 특징으로 하는 약제 조성물.
- 삭제
- 삭제
- 제 1항에 있어서, 암이 간세포암임을 특징으로 하는 약제 조성물.
- 제 1항에 있어서, 포유동물이 인간임을 특징으로 하는 약제 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 암세포에 대해 알파페토프로테인 펩티드 특이적 T 림프구를 활성화시키는 것을 포함하는 면역 반응을 생성시키기에 충분한 알파페토프로테인 분자의 아미노산 서열의 일부 또는 이의 변형체를 코드화하는 폴리누클레오티드를 포함하며, 알파페토프로테인 분자의 아미노산 서열의 일부가 SEQ ID NO:2의 잔기 1-9, SEQ ID NO:2의 잔기 12-20, SEQ ID NO:2의 잔기 158-166, SEQ ID NO:2의 잔기 178-186, SEQ ID NO:2의 잔기 235-243, SEQ ID NO:2의 잔기 287-295, SEQ ID NO:2의 잔기 404-412, SEQ ID NO:2의 잔기 441-450, SEQ ID NO:2의 잔기 492-500, SEQ ID NO:2의 잔기 542-550, SEQ ID NO:2의 잔기 547-556 및 SEQ ID NO:2의 잔기 555-563으로 구성된 군으로부터 선택되고, 변형체가 SEQ ID NO:3 또는 SEQ ID NO:4인, 포유동물의 암을 예방하거나 치료하기 위한 약제 조성물.
- 삭제
- 제 11항에 있어서, 폴리누클레오티드가 발현 벡터에 함유됨을 특징으로 하는 약제 조성물.
- 제 1항에 열거된 알파페토프로테인 분자의 일부 또는 이의 변형체를 발현하는 재조합 벡터로 형질도입된 수상 세포를 포함하는, 포유동물의 암을 치료하거나 예방하기 위한 약제학적 조성물.
- 삭제
- 삭제
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3837597P | 1997-02-13 | 1997-02-13 | |
US60/038,375 | 1997-02-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20000071226A KR20000071226A (ko) | 2000-11-25 |
KR100460583B1 true KR100460583B1 (ko) | 2004-12-08 |
Family
ID=21899585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-1999-7008375A KR100460583B1 (ko) | 1997-02-13 | 1998-02-13 | 간세포 암의 예방 및 치료 방법 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20020031520A1 (ko) |
EP (1) | EP0979239B1 (ko) |
JP (3) | JP3816959B2 (ko) |
KR (1) | KR100460583B1 (ko) |
CN (2) | CN1222536C (ko) |
AU (1) | AU6435398A (ko) |
DE (1) | DE69836209D1 (ko) |
WO (1) | WO1998035981A1 (ko) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1253930A4 (en) * | 2000-02-10 | 2003-05-21 | Univ California | METHODS AND COMPOSITIONS FOR TREATING HEPATOCELLULAR CANCER |
FI118263B (fi) * | 2002-10-09 | 2007-09-14 | Timo Kalevi Korpela | Kaspaasiaktiivisuutta säätelevät peptidit |
US8932829B2 (en) | 2005-07-07 | 2015-01-13 | Elena Dudich | Recombinant alpha-fetoprotein and compositions thereof |
GB0617564D0 (en) * | 2006-09-06 | 2006-10-18 | Ucl Business Plc | Peptides and methods |
KR100900742B1 (ko) * | 2007-05-17 | 2009-06-08 | 크레아젠 주식회사 | 인간 간암 동물모델 및 이를 이용한 수지상세포-유래 간암면역치료제의 예방 및 치료 효능을 분석하는 방법 |
WO2011048503A2 (en) * | 2009-10-22 | 2011-04-28 | Moro Ricardo J | Peptides that bind the alpha-fetoprotein (afp) receptor and uses thereof |
WO2014093118A1 (en) | 2012-12-11 | 2014-06-19 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for high throughput receptor:ligand identification |
US20180208658A1 (en) | 2015-04-03 | 2018-07-26 | Eureka Therapeutics, Inc. | Constructs targeting afp peptide/mhc complexes and uses thereof |
CN105126074A (zh) * | 2015-09-30 | 2015-12-09 | 中国药科大学 | 多肽afp12在制备抗肿瘤药物中的应用 |
CN105524884A (zh) * | 2016-02-29 | 2016-04-27 | 时宏珍 | Hla-a0201限制性抗afp抗原特异性ctl的制备方法 |
JP2019522466A (ja) | 2016-05-18 | 2019-08-15 | アルバート アインシュタイン カレッジ オブ メディシン,インコーポレイティド | 変異pd−l1ポリペプチド、t細胞調節多量体ポリペプチド、及びそれらの使用方法 |
BR112018073606A2 (pt) | 2016-05-18 | 2019-02-26 | Cue Biopharma, Inc. | polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos |
CN116970061A (zh) | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
EP3596118A4 (en) | 2017-03-15 | 2021-04-07 | Cue Biopharma, Inc. | PROCESSES FOR MODULATING AN IMMUNE RESPONSE |
EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF |
CA3169949A1 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
CN113416729B (zh) * | 2021-05-18 | 2022-11-22 | 遵义医科大学附属医院 | 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH025866A (ja) * | 1988-06-27 | 1990-01-10 | Kansai Shin Gijutsu Kenkyusho:Kk | ヒトアルファフェトプロテインドメインi遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインiの製造法及び製造された該ドメインi |
IT1226551B (it) * | 1988-07-29 | 1991-01-24 | Sclavo Spa | Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico |
US5633234A (en) * | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
JPH10513347A (ja) * | 1995-01-24 | 1998-12-22 | ロバート エイ. マルギタ | 組換え型ヒトα−フェトプロテインおよびその利用 |
-
1998
- 1998-02-13 WO PCT/US1998/002753 patent/WO1998035981A1/en active IP Right Grant
- 1998-02-13 KR KR10-1999-7008375A patent/KR100460583B1/ko not_active IP Right Cessation
- 1998-02-13 EP EP98910001A patent/EP0979239B1/en not_active Expired - Lifetime
- 1998-02-13 JP JP53591698A patent/JP3816959B2/ja not_active Expired - Lifetime
- 1998-02-13 CN CNB988052288A patent/CN1222536C/zh not_active Expired - Lifetime
- 1998-02-13 CN CNA2005100915162A patent/CN1739791A/zh active Pending
- 1998-02-13 AU AU64353/98A patent/AU6435398A/en not_active Abandoned
- 1998-02-13 DE DE69836209T patent/DE69836209D1/de not_active Expired - Lifetime
-
1999
- 1999-08-12 US US09/373,913 patent/US20020031520A1/en not_active Abandoned
-
2006
- 2006-02-15 JP JP2006038626A patent/JP2006188528A/ja not_active Withdrawn
-
2010
- 2010-06-30 JP JP2010150627A patent/JP2010222379A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU6435398A (en) | 1998-09-08 |
CN1222536C (zh) | 2005-10-12 |
EP0979239A4 (en) | 2002-09-18 |
EP0979239B1 (en) | 2006-10-18 |
CN1739791A (zh) | 2006-03-01 |
EP0979239A1 (en) | 2000-02-16 |
JP2001515347A (ja) | 2001-09-18 |
US20020031520A1 (en) | 2002-03-14 |
KR20000071226A (ko) | 2000-11-25 |
JP2010222379A (ja) | 2010-10-07 |
DE69836209D1 (de) | 2006-11-30 |
JP3816959B2 (ja) | 2006-08-30 |
CN1259139A (zh) | 2000-07-05 |
WO1998035981A1 (en) | 1998-08-20 |
JP2006188528A (ja) | 2006-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100460583B1 (ko) | 간세포 암의 예방 및 치료 방법 | |
EP2280031B1 (en) | Cancer antigens based on products of the tumor suppressor gene WT1 | |
KR100653590B1 (ko) | 시클로필린 b 유래의 종양 항원 펩티드 | |
JP3759738B2 (ja) | 免疫原性ペプチド | |
JP4904384B2 (ja) | 新規な腫瘍抗原タンパク質sart−3、およびその腫瘍抗原ペプチド | |
JP5114403B2 (ja) | Hla−a3スーパータイプアレル陽性前立腺癌患者に対する癌ワクチン療法に有用なsart3由来ペプチド | |
EP1536006B1 (en) | Cancer antigens and utilization thereof | |
KR20060003903A (ko) | 사람 암배아 항원을 암호화하는 합성 유전자 및 이의 용도 | |
AU757726B2 (en) | Novel tumor antigen protein art-1 and tumor antigen peptide thereof | |
EP1103561B1 (en) | Hla-a2 restraint tumor antigen peptide originating in sart-1 | |
JP4925033B2 (ja) | ストレス誘導抗アポトーシス分子(iex−1)由来ペプチド | |
WO2005007694A1 (ja) | HER2/neuペプチドおよびその治療上の用途 | |
BENGA et al. | Workshop Q Tumor Immunology | |
BECKER et al. | WORKSHOP 0 Tumor Immunology | |
KR20110128008A (ko) | Rna 전이 항원 제시 세포를 이용한 신규 종양항원의 규명 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121107 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20131108 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20141107 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20151109 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20161111 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20171110 Year of fee payment: 14 |
|
EXPY | Expiration of term |